New York, December 13, 2021/PRNewswire/ - Independent investment research company Argus Research has released a stock research report on G Medical Innovations Holdings Ltd. (NASDAQ: GMVD)

Click here to view the complete Argus stock research report.

Company highlights: Excerpts (conveyed by Argus analyst Steve Silver) include:

GMVD: Promoting innovation in mobile health and telemedicine:

G Medical’s current products include Prizma, a clinical-grade device that allows smartphones to be used for medical monitoring, and the Extended Holter Patch System, a biosensor that can continuously capture ECG data for up to 14 days.

The company is also developing a wireless vital signs monitoring service, which we believe can generate recurring revenue through monthly subscription fees.

In our view, compared with products provided by peers who only capture ECG data or focus only on fitness applications, G Medical has a set of differentiated products and services. In contrast, Prizma aims to provide more detailed data than competing devices and make it easier for consumers to understand these data. We also hope that the company can benefit from a leadership team with many years of experience in the mobile health industry.

The company raised $13.4 million in its initial public offering in June 2021. We expect that the proceeds will be used to expand the sales force, complete the vital signs monitoring system, and develop new products.

Based on our valuation analysis, our estimated fair value of GMVD is US$5.50 per share, which is much higher than the current level.

Excerpts from investment papers (click here to view the full Argus stock research report):

G Medical Innovations Holdings Inc., headquartered in Israel, was established in 2014 and is dedicated to the development and manufacturing of mobile health products. It also provides telemedicine services to help patients manage medical conditions, especially in areas such as cardiovascular disease, lung disease and diabetes. The company's current products include Prizma, a clinical-grade device that allows smartphones to be used for medical monitoring, and the Extended Holter Patch System, a biosensor that can continuously capture electrocardiogram (ECG) data for up to 14 days. The company is also developing a wireless vital signs monitoring system (VSMS), which will provide real-time diagnostic and monitoring services.

In our view, G Medical is capable of participating in the fast-growing "mHealth" or mobile health industry. Grand View Research predicts that by the end of 2021, the mobile medical market will reach 53.6 billion U.S. dollars, and by 2028 it will reach 166 billion U.S. dollars (compound annual growth rate of 17.6%). We believe that the growth of mobile healthcare will be driven by more use of wearable devices and an increase in chronic diseases.

We have noticed that telemedicine provides a cost-effective alternative to traditional care for many medical conditions. It also provides basic health care services for patients when they cannot go to the doctor’s office or hospital-this often happened during last year’s pandemic lockdown. According to data from McKinsey, telemedicine accounted for 46% of medical consultations in April 2020, up from 11% in 2019. Although we believe that this percentage may decline as the pandemic subsides, we believe that the pandemic has made telemedicine acceptable to a large number of patients. Consumers, many people will continue to use telemedicine services in the future.

G Medical faces competition in the wearable medical device market, from AliveCor (its products only capture ECG data), Qardio (focusing on blood pressure tracking) and Tytocare (focusing on home health check-ups) and Apple watches. However, G Medical believes that Prizma provides more detailed data than most competing devices, especially in terms of cardiovascular and lung health, and it makes it easier for consumers to understand these data.

Prizma uses a wireless Bluetooth connection to connect to any smartphone. It enables users to obtain an electrocardiogram and measure various vital signs, including oxygen saturation, temperature, heart rate, and pressure level. Users can also manually enter blood pressure, weight, and blood glucose measurements and track them on Prizma's app and cloud portal. In addition, users can generate reports based on the data and share them with medical professionals or family members, which we believe can have a beneficial impact on patient compliance and results. Prizma will also integrate with the company's wireless vital signs monitoring system to provide enhanced real-time monitoring.

The company's product portfolio also includes the Extended Holter Patch System, a multi-channel biosensor that can continuously capture ECG data for up to 14 days. G Medical believes that multi-channel ECG can provide higher predictive values ​​through more actionable data, thereby helping doctors make more accurate diagnoses. In addition, the system allows patients to capture symptom events by clicking a button on the recorder and recording their symptoms in the patient's diary. This associates the ECG with specific patient activities and provides doctors with important contextual data. After the monitoring session, the patient returns the device to G Medical, and then uploads the data to the secure cloud for analysis. Then, a certified cardiac technician will generate a concise clinical report based on the ECG. The report is verified through a quality assurance process and made available to the patient’s doctor on the company’s secure portal. In view of the rise of telemedicine and e-health and the advantages of this system in helping doctors diagnose, we believe that the extended Holter patch system may become the company's main source of income.

Prizma has obtained European CE mark approval, FDA 510 K approval and emergency over-the-counter (OTC) authorization in the United States. G Medical expects that OTC approval will remain valid throughout the COVID-19 pandemic. Holter Patch has also received FDA emergency use authorization and is ready for commercialization. In addition, Prizma has been approved by Australian, Taiwanese and Italian regulatory agencies, and Holter Patch has been approved in Australia. G Medical is also preparing to submit a Prizma application to the National Medical Products Administration (NMPA) of China.

In addition to commercializing Prizma and Extended Holter Patch System in the United States, China and other markets, G Medical is completing the development of its wireless vital signs monitoring system, which aims to provide continuous real-time monitoring of a wide range. vital signs. The management hopes that the system will generate recurring revenue streams in the form of monthly remote monitoring fees paid by hospitals, insurance companies, chronic disease care management companies, and individual patients through direct-to-consumer channels. It also hopes to generate recurring income from the monthly fees used by Prizma.

The mobile medical industry is characterized by strong R&D capabilities, rapid innovation, and more independent software development. The competition in the next ten years may be very fierce. However, we believe that G Medical has the potential to open up a space in the field of health telemetry and monitoring. The company has 3 technical patents and 11 patent applications. It currently produces products in Israel, but it is expected to find lower-cost manufacturing options in China or other locations, which we believe will help increase gross profit margins over time.

About G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) gmedinnovations.com

G Medical Innovations Holdings Inc., headquartered in Israel, was established in 2014 and is committed to developing and manufacturing mobile health products and providing telemedicine services. The company's products include Prizma, a clinical-grade device that enables smartphones to be used for medical monitoring, and Extended Holter Patch, a biosensor that captures ECG data. G Medical is also developing wireless vital signs monitoring services. The company has 3 technical patents and 11 patent applications.

For more information, please contact:

Senior Vice President of G-Medical Innovations Ltd Adv. Oded Shahar and acquisition of info@gmedinnovations.com

Argus Research (www.argusresearch.com), headquartered in New York City, is a leading independent equity research company (founded in 1934). It provides information on more than 1,600 companies in all 11 sectors of the Standard & Poor’s 500 Index, as well as macroeconomic fundamentals. Quantitative research and stock market forecasts, special studies, model portfolios and pre-market research. In addition, Argus has recently committed to providing sponsored research solutions for small and medium-sized companies seeking coverage. Argus’ stock research and earnings forecasts are available on major research/earnings forecast aggregation platforms, including Bloomberg, Thomson Reuters, Factset and S&P Global.

For more information, please contact:

Darrell Stone 646-747-5438 dstone@argusresearch.com

As part of the sponsored research agreement between Argus and the company, Argus Research has collected fixed fees from the companies discussed in this report. Any remuneration from Argus Research is not directly or indirectly related to the content of this evaluation or other opinions expressed in this report. Please refer to the full Argus report and disclaimer for complete disclosure.

View original content and download multimedia: https://www.prnewswire.com/news-releases/argus-research-initiates-equity-research-report-coverage-on-g-medical-innovations-holdings-ltd-nasdaq-gmvd- 301442548.html

After a quick recovery from the Omicron panic, the stock market looks set to start a busy week, with the central bank taking the lead. As some hawkish signals are expected, the market may experience a round of volatility at the close of 2021, although some policy changes, especially the Fed’s policy changes, have been communicated in advance to allow investors to be prepared. European stock index futures are at a loss after gains in Asia. After the S&P 500 index set its 67th closing high this year on Friday, U.S. futures also pointed north. Investors began to pay attention to Apple becoming the first company with a market value of 3 trillion US dollars. . From Russia to Mexico, a large number of central banks in emerging markets will raise interest rates, followed by the European Central Bank and the Bank of England.

ATS Automated Tool Systems (TSX: ATA) ("ATS" or "Company") today announced that the Toronto Stock Exchange ("TSX") has accepted the company's bid for regular course issuers ("NCIB") ) Notice of intent. ").

As of 12:30 pm Eastern Time on Tuesday, creative software leader Adobe (NASDAQ: ADBE) shares have fallen by 7.6%. The culprit may be Sterling Auty, a stock analyst at JPMorgan Chase (NYSE: JPM), who downgraded the stock to neutral and set a one-year price target of $680. Adobe and some of its software counterparts have been hit by the forecasters’ view that they have limited upside in 2022. However, according to records, after the decline on Tuesday morning, the target price of $680 still means that Adobe now has about 12% upside trade.

Microsoft (NASDAQ: MSFT) shares closed down 3.3% on Tuesday after the US Department of Labor reported that producer price inflation in November hit a record high, up 9.6% year-on-year. The news came before the 6.8% increase in consumer prices announced yesterday-the fastest price increase in 40 years. When Bloomberg reported that Microsoft's stock price fell, it drew clues to Microsoft's stock price weakness directly from the inflation data. Think about it this way: Currently, analysts tracking Microsoft stock predict that the company's annual revenue will grow by about 15% in the next five years.

At a basic level, all companies have the same goals-only some companies are good at it.

As we enter 2022, stock selection may be the key, uncertainty is entering the market and opening the door to potential volatility.

Our appeal from Stifel that day believes that the Fed is working hard to create a bubble of the century. This is what happened before.

(Bloomberg)-Former US Secretary of the Treasury Lawrence Summers warned that retail purchases and enthusiastic investors have pushed up the risk of "spontaneous financial market contraction." Can Paradise Indoor Farm reach the height of a skyscraper? China is building the world’s largest national park system. Boris Johnson’s angry members of Congress worry that his next mistake may be fatal, with "a lot of euphoria," Summers said.

Investors are reminded to pay attention to several risk factors that need to be considered for this investment.

Making progress in promoting the transition to a hydrogen economy, Plug Power (NASDAQ: PLUG) today announced the signing of a long-term supply and logistics agreement. However, considering that the details of the partnership are quite small, investors are not impressed. As of 12:14 pm Eastern Time, Plug Power's stock price has fallen 6.2%. Although Plug Power initially made money by providing fuel cell systems, the company has articulated its long-term vision of diversifying its business by producing green hydrogen.

The Supreme Court will not block the authorization of New York's healthcare vaccines, Apple is preparing to become the first company with a market value of $3 trillion, MGM Resorts selling Mirage Hotel to Hard Rock, and other news to start a new day.

Is the bear finally waking up from hibernation? Goldman Sachs said it was not so fast. Volatility has recently dominated Wall Street, leading some to conclude that those with a more pessimistic outlook have been proven correct, but the company believes that the stock market can still climb. According to David Costin, head of US equity strategy at Goldman Sachs, the S&P 500 index may reach 5,100 points next year. If the index finally reaches this target, it will reflect a 10% return. "If you are looking for a good

Sunrun (NASDAQ: RUN) shares fell on Tuesday after a regulatory proposal threatened a slowdown in the growth of the solar industry. As of 3:25 pm Eastern Time, Sunrun's stock price has fallen by more than 13%. The proposed changes to California's net energy metering program may significantly increase consumer costs and eliminate "tens of thousands of jobs." Fenster said in a press release that it “represents the worst aspect of California politics, while ignoring what voters want—innovation, control, and quick solutions—but supporting failed and boring incumbents. "

In the long run, investing in emerging technologies can bring substantial returns to investors.

Salesforce.com (NYSE: CRM), a customer relationship management software company, fell sharply on Tuesday. As of this writing, the Nasdaq Composite Index, which is dominated by technology stocks, is down more than 2%. Salesforce's decline came shortly after the company announced its strong third-quarter results, but its guidance for the fourth quarter of fiscal year 2022 was mixed.

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) ("Aurora") is a Canadian company that defines the future of global cannabinoids, and 22nd Century Group, Inc. (NASDAQ: (Stock code: XXII) ("22nd Century") together announced today that a tripartite non-exclusive agreement licenses biosynthetic intellectual property rights to Cronos Group Inc. (NASDAQ: CRON) (TSX code: CRON) ("Cronos Group"), aims to assist in the advancement of biosynthetic research and development of cannabinoids.

The CEO made a big bet on Bitcoin. But he is not alone.

The inflation rate is at the highest level in the past four years, but you can take some measures to eliminate the pressure through your personal finances.

The share prices of Roku (NASDAQ: ROKU), Snowflake (NYSE: SNOW) and DraftKings (NASDAQ: DKNG) all fell more than 6%, and then rebounded slightly. First of all, they are both very high multiple growth stocks. Traders seem to worry that at the Fed meeting this week, officials may decide to accelerate the pace of financial tightening, which may damage these types of stocks in terms of finances and valuation. Fed officials will meet on Tuesday and Wednesday and may discuss a faster reduction in bond purchases, which reflects Fed Chairman Jerome Powell’s comments earlier this month.

(Bloomberg)-Microsoft fell on Tuesday, and the software company led the decline among large Internet and technology stocks. Most of the reading comes from Bloomberg. Zero taxes, golf and beach villas have created a crypto island paradise. Can indoor farms reach the height of skyscrapers? China is building the world's largest national park system Boris Johnson's angry congressmen worried that his next mistake could be fatal. The stock fell 3.3%, the biggest one-day percentage drop since September. One day's fall erased more